United Therapeutics Corporation (UTHR) — Form 10-Q: Quarterly report

United Therapeutics Corporation filed its quarterly report for the period ended September 30, 2026. During the third quarter, the company repurchased 980,394 shares for an average price of $532.63 per share under its share repurchase programs and Rule 10b5-1 trading plans. Additionally, the company entered into an amendment to its exclusive license agreement with Arena on November 3, 2026, paying a lump-sum of $525.0 million to eliminate future royalty obligations on ralinepag products.